financetom
Business
financetom
/
Business
/
BP Sees Sequentially Higher Upstream Output in Q3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BP Sees Sequentially Higher Upstream Output in Q3
Oct 14, 2025 4:41 AM

07:01 AM EDT, 10/14/2025 (MT Newswires) -- BP (BP) said in a regulatory filing on Tuesday that it now expects upstream output to be higher in Q3 compared with the prior quarter.

That compares with the oil and gas giant's August forecast of slightly lower upstream production in Q3 compared with Q2.

BP also said it expects higher output in both the oil production and operations segment, driven by higher gas production at bpx energy, as well as in gas and low carbon energy.

BP shares were down 3% in recent Tuesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
May 31, 2025
* Trodelvy/Keytruda patients had 11.2 months progression-free survival vs 7.8 months for chemotherapy/Keytruda * ASCO says Trodelvy/Keytruda likely to become standard of care * Patients still being followed to see if combination extends survival By Deena Beasley May 31 (Reuters) - Gilead Sciences' ( GILD ) Trodelvy in combination with Merck's ( MRK ) blockbuster immunotherapy Keytruda lowered the risk...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
May 31, 2025
May 31 (Reuters) - An experimental treatment by Pfizer ( PFE ) and Arvinas ( ARVN ) delayed progression of breast cancer by more than three months compared to AstraZeneca's ( AZN ) Faslodex in patients with a specific gene mutation, according to trial results announced on Saturday. The findings were presented in Chicago at the annual meeting of the...
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
May 31, 2025
(Reuters) -Gilead Sciences' ( GILD ) Trodelvy in combination with Merck's ( MRK ) blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday. The data is likely to change how patients are treated following a diagnosis for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved